PLA2R1 promotes DNA damage and inhibits spontaneous tumor formation during aging.


Journal

Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092

Informations de publication

Date de publication:
16 02 2021
Historique:
received: 24 03 2020
accepted: 21 01 2021
revised: 16 01 2021
entrez: 17 2 2021
pubmed: 18 2 2021
medline: 15 9 2021
Statut: epublish

Résumé

Although aging is a major risk factor for most types of cancers, it is barely studied in this context. The transmembrane protein PLA2R1 (phospholipase A2 receptor) promotes cellular senescence, which can inhibit oncogene-induced tumor initiation. Functions and mechanisms of action of PLA2R1 during aging are largely unknown. In this study, we observed that old Pla2r1 knockout mice were more prone to spontaneously develop a wide spectrum of tumors compared to control littermates. Consistently, these knockout mice displayed increased Parp1, a master regulator of DNA damage repair, and decreased DNA damage, correlating with large human dataset analysis. Forced PLA2R1 expression in normal human cells decreased PARP1 expression, induced DNA damage and subsequent senescence, while the constitutive expression of PARP1 rescued cells from these PLA2R1-induced effects. Mechanistically, PARP1 expression is repressed by a ROS (reactive oxygen species)-Rb-dependent mechanism upon PLA2R1 expression. In conclusion, our results suggest that PLA2R1 suppresses aging-induced tumors by repressing PARP1, via a ROS-Rb signaling axis, and inducing DNA damage and its tumor suppressive responses.

Identifiants

pubmed: 33594040
doi: 10.1038/s41419-021-03468-3
pii: 10.1038/s41419-021-03468-3
pmc: PMC7887270
doi:

Substances chimiques

PLA2R1 protein, human 0
Pla2r1 protein, mouse 0
Reactive Oxygen Species 0
Receptors, Phospholipase A2 0
Retinoblastoma Protein 0
PARP1 protein, human EC 2.4.2.30
Parp1 protein, mouse EC 2.4.2.30
Poly (ADP-Ribose) Polymerase-1 EC 2.4.2.30

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

190

Références

Crit Rev Food Sci Nutr. 2004;44(4):275-95
pubmed: 15462130
Cancer Res. 2013 Oct 15;73(20):6334-45
pubmed: 24008317
Nat Commun. 2015 Jun 24;6:7505
pubmed: 26106036
Cancer Cell. 2007 Jan;11(1):25-36
pubmed: 17189716
Sci Rep. 2020 Jun 3;10(1):9058
pubmed: 32493972
J Pathol. 2007 Jan;211(2):124-33
pubmed: 17200941
Anticancer Res. 2016 Oct;36(10):5009-5017
pubmed: 27798859
Nature. 2015 Nov 12;527(7577):186-91
pubmed: 26466563
Nucleic Acids Res. 2007;35(22):7417-28
pubmed: 17913751
Semin Cancer Biol. 2019 Jun;56:116-127
pubmed: 29104026
Sci Transl Med. 2014 Jan 29;6(221):221ra15
pubmed: 24477002
Nature. 2006 Nov 30;444(7119):633-7
pubmed: 17136093
J Biol Chem. 2009 Nov 13;284(46):31532-40
pubmed: 19755417
Oncotarget. 2014 Feb 28;5(4):1004-13
pubmed: 24657971
Aging Cell. 2018 Dec;17(6):e12835
pubmed: 30216637
Nature. 2006 Nov 30;444(7119):638-42
pubmed: 17136094
Oncogene. 2016 Sep 22;35(38):5033-42
pubmed: 27041564
Proc Natl Acad Sci U S A. 2009 Jan 6;106(1):169-74
pubmed: 19118192
J Mol Med (Berl). 1996 Jun;74(6):297-312
pubmed: 8862511
EMBO Rep. 2009 Mar;10(3):271-7
pubmed: 19197340
Nat Cell Biol. 2006 Nov;8(11):1291-7
pubmed: 17028578
Sci Transl Med. 2015 Oct 7;7(308):308re8
pubmed: 26446958
JAMA. 2007 Feb 28;297(8):842-57
pubmed: 17327526
Nature. 2005 Apr 14;434(7035):864-70
pubmed: 15829956
J Natl Cancer Inst. 1996 Nov 6;88(21):1560-70
pubmed: 8901854
Oncogene. 2002 Dec 16;21(58):8981-93
pubmed: 12483514
Biochim Biophys Acta. 2014 Aug;1846(1):40-4
pubmed: 24667060
Exp Cell Res. 2008 Jun 10;314(9):1918-22
pubmed: 18282568
FASEB J. 2018 Jun 6;:fj201800092R
pubmed: 29874127
Carcinogenesis. 2009 Jan;30(1):2-10
pubmed: 18978338
Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7
pubmed: 7568133
Free Radic Biol Med. 2013 Dec;65:969-977
pubmed: 23994771
Free Radic Biol Med. 2012 Jan 1;52(1):7-18
pubmed: 22019631
Radiat Oncol. 2015 Aug 04;10:163
pubmed: 26238507
J Biol Chem. 1997 Dec 26;272(52):32792-7
pubmed: 9407054
Cancer Cell. 2010 Apr 13;17(4):376-87
pubmed: 20385362
JCI Insight. 2019 Oct 3;4(19):
pubmed: 31578304
Mutagenesis. 2002 Nov;17(6):529-38
pubmed: 12435850
Int J Cancer. 2004 Oct 10;111(6):813-8
pubmed: 15300792
Mutat Res. 2003 Jan 10;534(1-2):15-20
pubmed: 12504751
Cell Death Dis. 2018 Feb 15;9(3):259
pubmed: 29449545
DNA Repair (Amst). 2014 Jul;19:108-13
pubmed: 24755000
Mol Cancer Res. 2015 Apr;13(4):699-712
pubmed: 25828893
Nat Commun. 2016 Jan 29;7:10399
pubmed: 26822533
Nature. 2005 Apr 14;434(7035):907-13
pubmed: 15829965
J Biol Chem. 2002 May 3;277(18):15697-702
pubmed: 11867628

Auteurs

Anda Huna (A)

Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France.

Audrey Griveau (A)

Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France.

David Vindrieux (D)

Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France.

Sara Jaber (S)

Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France.

Jean-Michel Flaman (JM)

Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France.

Delphine Goehrig (D)

Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France.

Lamia Azzi (L)

INSERM U1053 Bordeaux Research in Translational Oncology, University of Bordeaux, Bordeaux Cedex, France.

Jean-Jacques Médard (JJ)

Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France.

Sophia Djebali (S)

Centre International de Recherche en Infectiologie, Inserm U1111, CNRS, UMR5308, École Normale Supérieure de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.

Hector Hernandez-Vargas (H)

Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France.

Robert Dante (R)

Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France.

Léa Payen (L)

Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France.

Jacqueline Marvel (J)

Centre International de Recherche en Infectiologie, Inserm U1111, CNRS, UMR5308, École Normale Supérieure de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, Lyon, France.

Philippe Bertolino (P)

Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France.

Sébastien Aubert (S)

Institut de Pathologie, Centre de Biologie Pathologie, CHRU de Lille, Faculté de Médecine, Université de Lille, Lille Cedex, France.

Pierre Dubus (P)

INSERM U1053 Bordeaux Research in Translational Oncology, University of Bordeaux, Bordeaux Cedex, France.
Plateau cellules tissus, CHU de Bordeaux, Pessac, France.

David Bernard (D)

Centre de Recherche en Cancérologie de Lyon, Inserm U1052, CNRS UMR 5286, Centre Léon Bérard, Université de Lyon, Lyon, France. david.bernard@lyon.unicancer.fr.

Articles similaires

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male
Humans Meals Time Factors Female Adult

Classifications MeSH